Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (GB:0A8E)
LSE:0A8E
Holding GB:0A8E?
Track your performance easily
0A8E Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.49 - $3.25
Previous Close$2.82
Volume520.00
Average Volume (3M)4.58K
Market Cap
$417.20M
Enterprise Value$609.43M
Total Cash (Recent Filing)$77.57M
Total Debt (Recent Filing)$269.80M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 07, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding148,998,825
10 Day Avg. Volume8,741
30 Day Avg. Volume4,580
Standard Deviation0.28
R-Squared0.00118
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-22.31
Price to Sales (P/S)3.07
Price to Cash Flow (P/CF)-10.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.45
Enterprise Value/Gross Profit4.51
Enterprise Value/Ebitda-34.31
Forecast
1Y Price Target
$5.25Price Target Upside86.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Xeris Pharmaceuticals News
PremiumCompany Announcements
Xeris Pharmaceuticals Appoints Kevin McCulloch as President and COO
PremiumCompany Announcements
Xeris Pharmaceuticals Undergoes Executive Leadership Transition
PremiumCompany Announcements
Xeris Pharmaceuticals Shareholders Back Key Proposals and Directors
Bulls Say, Bears Say
Bulls Say
LeadershipThe new CEO, John Shannon, outlined a 3-pronged approach for Xeris' future, focusing on maintaining rapid commercial growth, renewed commitment to financial discipline, and improving external communication to better set expectations for product growth and value creation.
Product DevelopmentXeris announced positive topline Phase 2 results for its once-weekly subcutaneous levothyroxine injection candidate utilizing its proprietary XeriSol platform technology.
Revenue GrowthGvoke revenues grew approximately 20% quarter-over-quarter and approximately 28% year-over-year, with market share reaching around 34%, primarily bolstered by new starts and increased awareness of the need for rescue glucagon products.
Bears Say
Adverse Events65% of participants reported at least one treatment-emergent adverse event, with fatigue being notable in 22% of cases, necessitating further understanding of XP-8121's tolerability profile in the upcoming Ph.3.
Financial PerformanceXeris reported financial results with total net product revenues of approximately $40 million, falling about 6% below analysts' estimates.
Operational IssuesGvoke’s underperformance versus expectations was related to a cyberbreach at Change Healthcare, resulting in a one-time loss of approximately $3 million in Gvoke revenues.
---
Options Prices
Currently, No data available
---
Ownership Overview
14.26% Insiders
8.47% Mutual Funds
22.10% Other Institutional Investors
55.17% Public Companies and
Individual Investors
0A8E FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest share price was $1.49 and its highest was $3.25 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Currently, no data Available
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Nov 07, 2024 which is in 42 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.097 by -$0.003.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is -$0.09.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 148,998,830 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.097. Following the earnings report the stock price went up 9.804%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Among the largest hedge funds holding Xeris Pharmaceuticals’s share is Fairfax Financial Holdings Ltd. It holds Xeris Pharmaceuticals’s shares valued at 385K.
---
Xeris Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.25 (86.04% Upside)
$5.25 (86.04% Upside)
Blogger Sentiment
Bullish
GB:0A8E Sentiment 75%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $20.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.90%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
---
0A8E Earnings Call
Q2 2024
0:00 / 0:00
---
0A8E Stock 12 Month Forecast
Average Price Target
$5.25
▲(86.04% Upside)
Technical Analysis
Xeris Pharmaceuticals
―
Aclaris Therapeutics
―
Aldeyra Therapeutics
―
Aurinia Pharmaceuticals
―
BioCryst
―
Best Analysts Covering 0A8E
1 Year
1 Year Success Rate
13/20 ratings generated profit
1 Year Average Return
+16.93%
reiterated a buy rating 2 months ago
Copying Roanna Ruiz's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +16.93% per trade.
---